Using Genomic Analysis to Guide Individual Treatment in Glioblastoma

ClinicalTrials.gov ID: NCT02725684

Public ClinicalTrials.gov record NCT02725684. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 3, 2026, 8:07 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to assess whether the use of genomics can help identify patient specific treatment choices in cancer. In order to test this, the investigators plan to use genomic sequencing technology to identify patient specific mutations in glioblastoma multiforme (GBM) as compared to normal cells to identify mutations. Further analysis will identify potential treatment targets and whether there are any drugs that could be used for these particular mutations. Follow up clinical data will be assessed to see if this individualized method of choosing treatment options can improve clinical outcomes in patients with GBM.

Study identification

NCT ID: NCT02725684
Recruitment status: Completed
Study type: Observational
Phase: Not listed
Lead sponsor: Rockefeller University; Other
Enrollment: 36 participants

Conditions and interventions

Conditions

Glioblastoma

Interventions

Observational study, no intervention Other

Other

Eligibility (public fields only)

Age range: 3 Years to 100 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Mar 12, 2015 (Actual)
Primary completion: Jul 7, 2017 (Actual)
Completion: Jul 7, 2017 (Actual)
Last update posted: Oct 25, 2017

2015 – 2017

United States locations

U.S. sites: 7
U.S. states: 1
U.S. cities: 2

Facility	City	State	ZIP	Site status
New York University Langone Medical Center	New York	New York	10016	—
Memorial Sloan Kettering Cancer Center	New York	New York	10017	—
Rockefeller University	New York	New York	10065	—
Weill Cornell Medical College	New York	New York	10065	—
Lenox Hill Hospital	New York	New York	10075	—
North Shore University Hospital	New York	New York	11030	—
Montefiore Medical Center	The Bronx	New York	10467	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT02725684, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Oct 25, 2017 · Synced Oct 3, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT02725684 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →